Abstract Aims Following treatment, cystic echinococcosis (CE) exhibits a relatively high relapse rate. Here, we evaluated the value of soluble programmed death‐1 (sPD‐1), sPD‐1 ligand (sPD‐L1) and anti‐recP29 antibody concentrations, as predictors of early surgical treatment outcomes in young CE‐affected patients. Methods and results This prospective study included 59 Tunisian children (177 plasmas), where CE was surgically treated and monitored for 3 post‐operative years. Based on CE post‐surgical development, patients were clustered into a ‘No relapsed’ CE (NRCE; n = 39) and a ‘Relapsed’ CE (RCE; n = 20) group. Plasma levels of sPD‐1, sPD‐L1 and anti‐recP29 IgG were measured using ELISA. In the NRCE group, sPD‐1, sPD‐L1 and anti‐recP29 IgG concentrations were significantly lower at D365 than at D30. By contrast, in the RCE group, no significant difference was observed between D0, D30 and D365. When considering individual variations, the probability to be ‘relapse‐free’ was 67% and 73% when anti‐recP29 IgG and sPD‐L1 level, respectively, decreased between D30 and D365. The probability to be ‘relapse‐free’ was 86% when the sPD‐1 level decreased between D30 and D365 ( P = .003; chi‐square test). Conclusion sPD‐1 may be a useful biomaker for the early evaluation of surgical procedure efficacy in paediatric CE cases.